Clinical trial NCT03997968: A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors
Official title: A Multi-Center, Open Label Phase 1/2 Study of CYT-0851 in Patients With Relapsed/Refractory B-Cell Malignancies and Advanced Solid Tumors
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Malignancy
Non-hodgkin Lymphoma
Multiple Myeloma
Breast Cancer
Ovarian Cancer
Soft Tissue Sarcoma
Head and Neck Cancer
DLBCL
Mantle Cell Lymphoma
Follicular Lymphoma
Pancreatic Cancer
CLL
Small Cell Lung Cancer
Squamous Cell Carcinoma of Head and Neck
Triple Negative Breast Cancer
Keywords: Oral MCT-inhibitor; refractory; B-cell; solid tumor
cancer
Lead sponsor: Cyteir Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2019-06-25
Enrollment: 169
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SEQUENTIAL
Primary purpose: TREATMENT

Brief summary: This clinical trial is an interventional, active-treatment, open-label, multi-center, Phase 1/2 study. The study objectives are to assess the safety, tolerability and pharmacokinetics (PK) of CYT-0851 in patients with relapsed/refractory B-cell malignancies and advanced solid tumors and to identify a recommended Phase 2 dose as a monotherapy and in combination with chemotherapy for evaluation in these patients.


Eligibility criteria: Key Phase 1 Inclusion Criteria

1. Male or female ≥18 years of age at time of informed consent.

   1. Female subjects of childbearing potential must be non-lactating, not pregnant as confirmed by a negative serum pregnancy test at most 30 days before enrollment and within 72 hours before the first administration of CYT-0851
   2. Female subjects of childbearing potential must not donate ova during the study and for at least 90 days after the last dose of study drug and must agree to continue using an effective method of contraception during the screening period to first study drug administration until 90 days after the last dose of study drug
   3. Male subjects who have not had a vasectomy must agree to use an effective method of contraception during the study and until 90 days after the last dose of the study drug, and to not donate sperm during the study and for at least 90 days after the last dose of study drug
2. ECOG Performance Status of 0-1
3. Measurable disease defined by disease-specific response criteria
4. Histologically-proven B cell malignancies, meeting the following criteria:

   1. Relapsed, refractory B-cell non-Hodgkin lymphoma requiring therapy, after at least two prior therapies, and if transplanted, then at least 3-month post autologous stem cell transplant and if CART-treated, then evidence of progression no sooner than 3 months post CART treatment, or
   2. Relapsed, refractory chronic lymphocytic leukemia requiring therapy after at least two prior therapies, including BTK and BCL-2 inhibitor therapy (unless ineligible for such therapy), or
   3. For multiple myeloma, relapsed or progressive on or after treatment with at least three prior therapies that included a proteasome inhibitor, an imide, daratumumab, and if transplant eligible, a bone marrow transplant (unless unfit for transplant), or
5. Histologically-proven solid tumor meeting the following criteria:

   1. Patients must have failed, refused, or not be eligible for further standard therapies (including chemotherapy, hormonal therapies, Her-2 directed therapies, as appropriate) expected to provide clinical benefit, and meeting the following criteria
   2. Metastatic breast cancer (including ER/PR positive or negative, Her-2 positive and negative, triple negative), treated with at least 1 prior therapy for metastatic disease, or
   3. Recurrent squamous cell carcinoma of the head and neck (HNSCC) (dose escalation) or human papilloma virus positive (HPV+) HNSCC (dose-escalation and backfill), treated with at least 1 prior therapy, or
   4. Ovarian cancer, progressive after treatment with at least prior platinum-based chemotherapy, and therapy with a PARP inhibitor or
   5. Soft tissue sarcoma, treated with at least one line of prior systemic therapy, or
   6. Recurrent metastatic or locally advanced pancreatic cancer after first line chemotherapy (backfill or combination patients only) or
   7. Histologically-proven advanced small-cell lung cancer (SCLC) (monotherapy backfill patients only).

      1. Patients with mixed histology are not allowed
      2. Prior treatment with platinum containing chemotherapy regimen with no evidence of progression within 90 days of last dose of platinum agent and anti-PD-(L)1 unless contraindicated
      3. At least 1 prior line of chemotherapy, but no more than 3 prior lines of therapy
6. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure
7. Willing and able to comply with the requirements of the study protocol
8. Site of disease amenable to a biopsy and willing to undergo biopsy required for backfill, or for dose-escalation if considered unsafe (approval to participate in the study required by the Medical Monitor) provide an archival sample ≤ 12 months old

Key Phase 2 Inclusion Criteria

1. Male or female ≥18 years of age at time of informed consent.

   1. Female subjects of childbearing potential must be non-lactating, not pregnant as confirmed by a negative serum pregnancy test at most 30 days before enrollment and within 72 hours before the first administration of CYT-0851
   2. Female subjects of childbearing potential must not donate ova during the study and for at least 90 days after the last dose of study drug and must agree to continue using, an effective method of contraception during the screening period to first study drug administration until 90 days after the last dose of study drug
   3. Male subjects who have not had a vasectomy must agree to use an effective method of contraception during the study and until 90 days after the last dose of the study drug, and to not donate sperm during the study and for at least 90 days after the last dose of study drug
2. ECOG Performance Status of 0-1
3. Measurable disease defined by disease-specific response criteria
4. Site of disease amenable to a biopsy and willing to undergo a biopsy for the determination of biomarker status, or, if considered unsafe (approval to participate in the study required by the Medical Monitor), archival sample ≤ 12 months old for determination of biomarker status.
5. Biomarker positive on recent biopsy or bone marrow sample if required for the specific cohort.
6. Histologically-proven B cell malignancies, meeting the following criteria:

   1. DLBCL Cohort

      1. Histologically-documented DLBCL or double hit lymphoma (B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and Burkitt lymphoma with BCL2 and MYC translocations (WHO Classification)
      2. Progressing on or after treatment with at least two prior lines of therapy, including R-CHOP or equivalent first line therapy
      3. If transplanted, then at least 3-month post autologous stem cell transplant
      4. If CART-treated, then evidence of progression no sooner than 3 months post CART treatment
   2. MCL Cohort

      1. Histologically-documented MCL
      2. Any stage at diagnosis
      3. Progressing on or after treatment with at least 2 prior lines of therapy, including a Bruton tyrosine kinase (BTK) inhibitor, after a 14-day washout period
   3. Multiple Myeloma Cohort

      1. Relapsed or progressing after treatment with at least 3 prior therapies that include a proteasome inhibitor, an Immunomodulatory imide drug (IMiD), daratumumab, and, if transplant eligible, a bone marrow transplant (unless unfit for transplant)
7. Or Histologically-proven solid tumors meeting the following criterial

   1. Patients must have failed, refused, or not be eligible for further standard therapies (including chemotherapy, hormonal therapies, Her-2 directed therapies, as appropriate) expected to provide clinical benefit, and meeting the following criteria
   2. Triple Negative Breast Cancer Cohort

      1. Histologically-documented triple negative breast cancer, ER/PR negative (defined as \<10% of cells expressing hormonal receptors via immunohistochemistry (IHC) analysis), and HER2-negative, defined as either of the following by local laboratory assessment:

         * In situ hybridization (ISH) non-amplified (ratio of HER2 to CEP17 \< 2.0 or single probe average HER2 gene copy number \< 4 signals/cell), or
         * IHC 0 or IHC 1+
      2. At least 1 prior line of chemotherapy, but no more than 5 prior lines of chemotherapy
   3. Ovarian Cancer Cohort

      1. Histologically-proven metastatic epithelial ovarian cancer
      2. Prior treatment with a platinum containing chemotherapy regimen
      3. At least 1 prior line of therapy, but no more than 5 prior lines of chemotherapy
   4. Pancreatic Cancer Cohort

      1. Histologically-proven metastatic or locally advanced pancreatic cancer
      2. At least 1 prior line of chemotherapy but no more than 4 prior lines of systemic therapy
   5. Soft Tissue Sarcoma Cohort 1) Histologically-proven advanced soft-tissue sarcoma excluding all types of adipocytic sarcoma and GIST 2) At least 1 prior line of systemic therapy (unless no standard of care exists), but no more than 5 prior lines of systemic therapy
8. Follicular Lymphoma Cohort

   1. Histologically-documented follicular lymphoma
   2. Relapsed, refractory follicular lymphoma requiring therapy, after at least two prior therapies, and if CART-treated, then evidence of progression no sooner than 3 months post CART treatment
9. Understands the procedures and requirements of the study and provides written informed consent and authorization for protected health information disclosure
10. Willing and able to comply with the requirements of the study protocol

Key Exclusion Criteria

1. Medical Conditions

   1. Known history of HIV
   2. Known history of viral hepatitis B unless HBV viral load is below the limit of quantification and off viral suppressive therapy
   3. Know history of hepatitis C unless antiviral treatment with curative intent completed and HCV viral load is below the limit of quantification.
   4. Myocardial infarction or stroke within 6 months
   5. Uncontrolled hypertension (systolic blood pressure (SBP) \> 160 or diastolic blood pressure (DBP) \>100 on maximal medical therapy)
   6. History of interstitial pulmonary disease
   7. Unresolved pneumonitis
   8. Grade ≥ 3 neuropathy
   9. Known active central nervous system (CNS) metastases. Subjects with previously treated CNS metastases may participate as long as clinically and radiologically stable for at least 4 weeks after treatment, have no evidence of new or enlarging lesions and are off steroids and asymptomatic for 28 days prior to dosing with study medication
   10. Known history of meningeal involvement or meningeal carcinomatosis
   11. Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for \> 2 weeks prior to screening visit
   12. Presence of clinically significant cataracts
   13. Second malignancy, except treated basal cell or localized squamous skin carcinomas, localized prostate cancer, or other malignancy that is in remission or stable and for which patients have not been on active anti-cancer therapy for 2 years
   14. Pregnant or lactating. If β-HCG is elevated, eligible if ultrasound confirms absence of a pregnancy.
   15. Dementia or significantly altered metal status
   16. Bowel obstruction requiring medical management less than 4 weeks prior to screening
   17. Inability to tolerate oral intake that includes 2 full meals per day (or equivalent) or swallow pills.
   18. Recurrent ascites requiring paracentesis more frequently than every 4 weeks or within 14 days of screening.
   19. Weight loss of more than 10% over the preceding 3 months prior to screening
2. Prior/Concomitant Therapy

   1. Prior allogeneic stem cell transplant
   2. On systemic antibiotic, antifungal or anti-viral therapy
   3. White blood cell (WBC) growth factors administered within 14 days of screening visit
   4. Cancer therapy within 14 days prior to treatment with study drug
   5. On narrow therapeutic index medications that are sensitive substrates of CYP3A, P-gp or BCRP (or caution is warranted with approval by the Sponsor).
   6. On any drug known to prolong QTc interval (eg, certain antiarrhythmic, antimicrobials) that cannot be discontinued or interrupted 72 hours before the Day 1 dose through Day 2, and 72 hours before the Day 15 dose until Day 16 (BID dosing) or the Day 22 dose until Day 23 (QD dosing), in Cycle 1 (see Section 7.6.1 for a list of drugs).
   7. On systemic corticosteroid treatment for non-tumor indication at a daily dose equivalent to \>10mg of Prednisone
3. Prior/Concurrent Clinical Study Experience a. Participation in another clinical trial (unless in the observation phase, or an observational study), or exposure to any investigational agent within 14 days prior to treatment with study drug
4. Laboratory assessments

   1. Complete blood count (CBC):

      Monotherapy and Chemotherapy Combinations 1 and 2:
      1. ANC \< 1.0 × 10\^9/L
      2. PLT \< 75 × 10\^9/L
      3. Hgb \< 9.0 g/dL

         Chemotherapy Combination Group 3:

      1) ANC \< 1.5 × 10\^9/L 2) PLT \< 100 × 10\^9/L 3) Hgb \< 9.0 g/dL

      Monotherapy and Chemotherapy Combination Groups 1 and 2:
   2. Calculated Creatinine clearance (Cockcroft-Gault) \< 40 mL/min

Chemotherapy Combination Group 3:

b. Calculated Creatinine clearance (Cockcroft-Gault) \< 50 mL/min c. Hepatic function

1. AST \> 2.0 × ULN
2. ALT \> 2.0 × ULN d. Total bilirubin \> 1.5 x ULN e. Albumin \< 2.8 g/dL 5. ECG Exclusion a. Screening QTc interval \> 450 milliseconds for males and QTc \> 470 ms for females (corrected by Fridericia) 6. Other Exclusions

   1. Unwilling or unable to make all planned study visits
   2. Unwilling or unable to provide a recent biopsy or bone marrow sample prior to enrollment and during study; Note: certain exceptions may be permitted allowing archival specimens prior to treatment or for subjects where a specimen is not required for biomarker positive testing
   3. Significant medical diseases or conditions, as assessed by the Investigators and Cyteir that would substantially increase the risk-benefit ratio of participating in the study. This includes but is not limited to acute myocardial infarction, arterial thrombosis, significant gastrointestinal bleed, or unstable angina within the last 6 months uncontrolled diabetes mellitus, current active infections, severely immunocompromised state, and congestive heart failure New York Heart Association (NYHA) Class III-IV, left ventricular ejection fraction (LVEF) \< 40% d: Chemotherapy Combination Group 3 only: known history of dhydropyrimidine dehydrogenase deficiency

Primary outcomes:
measure: Part A: Incidence of dose limiting toxicity
timeFrame: 28 Days
measure: Part B: Objective response rate
timeFrame: 24 Weeks
measure: Part C: Incidence of dose limiting toxicity
timeFrame: 28 Days
measure: Part D: Incidence of dose limiting toxicity
timeFrame: 28 Days
measure: Part E: Incidence of dose limiting toxicity
timeFrame: 21 Days
Secondary outcomes:
measure: Part A: Incidence of adverse events and other safety measures
timeFrame: 28 Days
measure: Part C: Incidence of adverse events and other safety measures
timeFrame: 28 Days
measure: Part D: Incidence of adverse events and other safety measures
timeFrame: 28 Days
measure: Part E: Incidence of adverse events and other safety measures
timeFrame: 21 Days
measure: Part A: Assessment of pharmacokinetic parameters
timeFrame: Phase 1: 12 months
measure: Part C: Assessment of pharmacokinetic parameters
timeFrame: Phase 1: 12 months
measure: Part D: Assessment of pharmacokinetic parameters
timeFrame: Phase 1: 12 months
measure: Part E: Assessment of pharmacokinetic parameters
timeFrame: Phase 1: 12 months
measure: Part B: Assessment of pharmacokinetic parameters
timeFrame: Phase 1: 12 months
measure: Part A: Objective response rate
timeFrame: 24 months
measure: Part C: Objective response rate
timeFrame: 24 months
measure: Part D: Objective response rate
timeFrame: 24 months
measure: Part E: Objective response rate
timeFrame: 24 months
measure: Part B: Anti-tumor activity and by DOR
timeFrame: 24 months
measure: Part B: Anti-tumor activity by PFS
timeFrame: 24 months
measure: Part B: Anti-tumor activity by DCR
timeFrame: 24 months
measure: Part B: Anti-tumor activity by OS
timeFrame: 24 months
measure: Part B: Safety assessment
timeFrame: 24 months
Other outcomes:
Locations:
city: San Francisco
country: United States
facility: University of California San Francisco
state: California
city: Stanford
country: United States
facility: Stanford Comprehensive Cancer Center
state: California
city: Denver
country: United States
facility: Sarah Cannon Research Institute at HealthONE
state: Colorado
city: Sarasota
country: United States
facility: Florida Cancer Specialists and Research Institute
state: Florida
city: Boston
country: United States
facility: Massachusetts General Hospital
state: Massachusetts
city: Boston
country: United States
facility: Dana Farber Cancer Institute
state: Massachusetts
city: Ann Arbor
country: United States
facility: University of Michigan
state: Michigan
city: Rochester
country: United States
facility: Mayo Clinic
state: Minnesota
city: Hackensack
country: United States
facility: John Theurer Cancer Center at HUMC
state: New Jersey
city: New York
country: United States
facility: NYU Langone Health
state: New York
city: Oklahoma City
country: United States
facility: Oklahoma University-Stephenson Cancer Center
state: Oklahoma
city: Philadelphia
country: United States
facility: Thomas Jefferson University, Sidney Kimmel Cancer Center
state: Pennsylvania
city: Nashville
country: United States
facility: Sarah Cannon Research Institute at Tennessee Oncology
state: Tennessee
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
city: Seattle
country: United States
facility: University of Washington Seattle Cancer Center
state: Washington
city: Milwaukee
country: United States
facility: Medical College of Wisconsin
state: Wisconsin
Study officials:
affiliation: Cyteir Therapeutics
name: Markus Renschler, MD
role: STUDY_DIRECTOR
References: